Events

LSX World Congress w/ Mark Davies

Join our SVP of Informatics and Data, Mark Davies, at the LSX World Congress.

Drug discovery is ripe for disruption. A time consuming and expensive process, taking years and costing billions, the industry is crying out for faster and more accurate drug targets to test at clinical trials. However technology has not been able to keep up, until now. A panel of leaders discuss the future possibilities and applications, moderated by Steve Carney, Editor at Drug Discovery Today. Speakers include: 

  • Mark Davies, SVP Informatics and Data, Benevolent AI
  • Martin-Immanuel Bittner, CEO, Arctoris
  • Neil Sahota, United Nations Artificial Intelligence Advisor and Interim CEO ACSILabs
  • Marta Gaia Zanchi, Founder and Managing Partner, Nina Capital

Discussion

  • The role in cost cutting of new drug spend and development times – how big of an impact can AI have in time and cost saving?
  • Should biopharma companies be planning for a future in where AI is routinely used in discovery?
  • AI collaboration to target, identify and diagnose faster
  • Gaining insights from clinical trial data – should everyone be taking a data science approach to clinical trials, and how?

Panel title: How AI, machine learning & big data are disrupting the drug discovery & development landscape for faster and more accurate lead identification

Date: Wednesday May 11th  

Time: 14.00-14.45

Link to the event →


Mark Davies

SVP Informatics and Data

He has a background in molecular genetics and bioinformatics and has over 15 years of experience working on biomedical data representation, data analysis and application development. In 2001, he joined the London based biotechnology company Inpharmatica, where he was initially working on mining the output of the Human Genome Projects and eventually moved on to building Chemogenomics systems used by pharmaceutical companies, such as Bayer. Mark moved to the European Bioinformatics Institute (EMBL-EBI) as one of the founding members and technical lead for the ChEMBL resource - the largest open-source SAR database. Mark was also responsible for the successful transition of the SureChEMBL chemical patent system from Digital Science to the EMBL-EBI

More Posts

You Might Also Like

News
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
Blog
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
News
Notifications of persons discharging managerial responsabilities
May 5, 2022
News
PDMR Notification (Dr. Olivier Brandicourt)
May 5, 2022
News
PDMR Notification (Jean Raby)
May 5, 2022
News
Notifications of Major Holdings
Apr 29, 2022